Galectin Therapeutics, Inc. (Nasdaq: GALT) reports that GR-MD-02, its development-stage galectin-3 (gal-3) inhibitor, has shown a positive effect on vascular ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE